Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland.
Dermatology. 2017;233(2-3):175-177. doi: 10.1159/000479792. Epub 2017 Sep 5.
BACKGROUND/AIMS: Fumaric acid esters (FAEs) are a well-established efficacious systemic treatment for psoriasis. Recent recommendations from the European Medicines Agency suggest monitoring of full blood count every 4 weeks for the duration of therapy for psoriasis. The aim of our study was to assess the incidence of lymphopenia in patients taking FAEs and the impact of recent recommendations for our practice.
We reviewed 151 patients treated with FAEs for psoriasis between December 2013 and 2015.
Lymphopenia <700 × 109/L was detected within the last 12 months in 36/151 (24%) and lymphopenia <500 × 109/L in 10/151 (7%). Of 39 patients no longer on treatment, 7 (18%) stopped because of persistent lymphopenia.
The implementation of these recommendations would have significant resource implications and also likely influence the acceptability of FAEs to patients. Cessation of FAEs necessitates the need for alternative therapy, commonly biologic therapy.
背景/目的：富马酸酯（FAE）是一种成熟的、有效的全身性银屑病治疗药物。欧洲药品管理局最近的建议表明，在银屑病治疗期间，应每 4 周监测一次全血细胞计数。我们研究的目的是评估接受 FAE 治疗的患者发生淋巴细胞减少症的发生率，并评估这些建议对我们的临床实践的影响。
我们回顾了 2013 年 12 月至 2015 年期间接受 FAE 治疗的 151 例银屑病患者。
在过去 12 个月内，151 例患者中有 36 例（24%）检测到淋巴细胞减少症 <700 × 109/L，101 例中有 10 例（7%）检测到淋巴细胞减少症 <500 × 109/L。在 39 例不再接受治疗的患者中，有 7 例（18%）因持续的淋巴细胞减少症而停止治疗。
这些建议的实施将产生重大的资源影响，也可能影响患者对 FAE 的接受程度。停止使用 FAE 需要替代治疗，通常是生物治疗。
